An Open-label Randomized Phase II Study to Assess the Efficacy and Safety of Nintedanib Alone or in Combination With Capecitabine for Patients With Refractory Metastatic Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 07 Jan 2018
At a glance
- Drugs Capecitabine (Primary) ; Nintedanib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 09 Dec 2016 Status changed from withdrawn prior to enrolment to discontinued.
- 27 Oct 2016 Status changed from suspended to withdrawn prior to enrolment.
- 22 Aug 2016 Status changed from recruiting to suspended.